Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods.

ABSTRACT:

Aims

Head-to-head comparisons among SGLT2 inhibitors treatments in established heart failure remain absent. We conducted a systematic review of dedicated heart failure trials to assess indirectly the composite outcomes and individual clinical endpoints among SGLT2 inhibitor treatments.

Methods and results

We systematically reviewed randomized controlled trials comparing SGLT2 inhibitors versus placebo in patients with established heart failure. A Bayesian approach to network meta-analysis was applied. Five trials including four treatment strategies were included in this study. The composite of cardiovascular death or hospitalization for heart failure showed no significant difference in the comparison between dapagliflozin and empagliflozin (OR 1.00, 95% CI 0.66-1.55), dapagl

SUBMITTER: Chen HB 

PROVIDER: S-EPMC10053258 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature